Viatris Inc (VTRS)

Viatris is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. It supplies medicines to approximately 1 billion patients a year and operates in more than 165 countries and territories with more than 30,000 employees. The company was formed in November 2020 when Pfizer's Upjohn business combined with Mylan in a Reverse Morris Trust transaction. In 2025 it reported total revenues of $14.30 billion. It has more than 1,400 approved molecules and covers more than 10 major therapeutic areas, including cardiovascular disease, oncology, and infectious diseases such as HIV/AIDS, hepatitis and tuberculosis.

Its portfolio consists of generics (including complex products), globally recognized iconic brands, and a growing set of innovative medicines. The brands include Lipitor, Lyrica, Celebrex and Viagra. The pipeline includes selatogrel, cenerimod, sotagliflozin (Inpefa), a fast-absorbing meloxicam for acute pain, a low-dose estrogen weekly contraceptive patch, and phentolamine ophthalmic solutions for presbyopia and night vision impairment. In October 2025 it acquired Aculys Pharma, adding pitolisant and Spydia nasal spray rights in Japan. Viatris reports four segments: Developed Markets, Emerging Markets, JANZ, and Greater China. Recent divestitures include its biosimilars portfolio (to Biocon Biologics), its women's healthcare business, its India API business and its OTC business. In 2025 it began an enterprise-wide strategic review, with restructuring expected to cut its global workforce by up to about 10%. Its three strategic imperatives are driving the base business, fueling the innovative portfolio, and modernizing for sustainable growth.

Viatris serves patients through retail and pharmacy establishments, wholesalers, governments, institutions, physicians and other customers. It is a leading supplier of antiretrovirals for HIV/AIDS, with access programs in more than 100 countries. It also partners with other pharmaceutical companies, offering them access to its R&D, regulatory, manufacturing, supply chain and commercial platform, and enters licensing and collaboration agreements for development, manufacturing and commercialization.

Viatris owns 27 manufacturing, packaging and distribution sites on five continents, producing oral solid doses, injectables and complex dosage forms, with its significant manufacturing, packaging, warehousing and distribution activities located primarily in the U.S. Manufacturing of API and finished dosage forms combines internal and external operations. After selling its India API business, it relies on a supply agreement with the buyer and agreements with other manufacturers. It is working to remediate issues at its Indore, India oral finished dose facility in discussion with the FDA. The company is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India.